Cargando…
Idelalisib may have the potential to increase radiotherapy side effects
INTRODUCTION: Idelalisib is approved for the treatment of relapsed chronic lymphocytic leukemia together with Rituximab and for monotherapy of follicular B-cell non-Hodgkin’s lymphoma and small lymphocytic lymphoma. It is a potent and selective phosphatidylinositol 3-kinase-δ (PI3K-δ) inhibitor. PI3...
Autores principales: | Gryc, Thomas, Putz, Florian, Goerig, Nicole, Ziegler, Sonia, Fietkau, Rainer, Distel, Luitpold V., Schuster, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490234/ https://www.ncbi.nlm.nih.gov/pubmed/28659152 http://dx.doi.org/10.1186/s13014-017-0827-7 |
Ejemplares similares
-
Increase in non-professional phagocytosis during the progression of cell cycle
por: Hofmann, Alexander, et al.
Publicado: (2021) -
Non-Professional Phagocytosis Increases in Melanoma Cells and Tissues with Increasing E-Cadherin Expression
por: Unseld, Luzie Helene, et al.
Publicado: (2023) -
Kinase inhibitors increase individual radiation sensitivity in normal cells of cancer patients
por: Jost, Tina, et al.
Publicado: (2022) -
Role of tumor cell senescence in non-professional phagocytosis and cell-in-cell structure formation
por: Gottwald, Dorian, et al.
Publicado: (2020) -
Rate of individuals with clearly increased radiosensitivity rise with age both in healthy individuals and in cancer patients
por: Schuster, Barbara, et al.
Publicado: (2018)